Premium
Solubility‐Improved 10‐ O ‐Substituted SN‐38 Derivatives with Antitumor Activity
Author(s) -
Doi Hisashi,
Kida Tatsuya,
Nishino Kosuke,
Nakatsuji Masatoshi,
Sakamoto Shiho,
Shimizu Shota,
Teraoka Yoshiaki,
Tamura Yasuhisa,
Kataoka Yosky,
Inui Takashi
Publication year - 2017
Publication title -
chemmedchem
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.817
H-Index - 100
eISSN - 1860-7187
pISSN - 1860-7179
DOI - 10.1002/cmdc.201700454
Subject(s) - cytotoxicity , in vivo , solubility , chemistry , quinoline , stereochemistry , nuclear chemistry , medicinal chemistry , combinatorial chemistry , in vitro , organic chemistry , biochemistry , biology , microbiology and biotechnology
With the objective of improving the poor water solubility of the potent antitumor compound SN‐38, 10‐ O ‐substituted SN‐38 derivatives were developed by the introduction of fluoroalkyl, fluorobenzoyl, or bromobenzoyl groups. The 10‐ O ‐fluoropropyl‐substituted compound 2 {( S )‐4,11‐diethyl‐9‐(3‐fluoropropoxy)‐4‐hydroxy‐1 H ‐pyrano[3′,4′:6,7]indolizino[1,2‐ b ]quinoline‐3,14(4 H ,12 H )‐dione} was found to be 17‐fold more soluble than SN‐38 in phosphate‐buffered saline, and it exhibited a level of biological activity ≈50 % that of SN‐38 in a cytotoxicity assay using the prostate cancer cell line PC‐3. Five other derivatives did not show solubility improvements to the same extent, but their activities in cytotoxicity assays were nearly the same as that of SN‐38. In vivo studies of 2 with PC‐3 tumor‐bearing mice revealed that it has higher antitumor activity than SN‐38, even at lower dosage. These results will promote the medicinal chemistry application of 10‐ O ‐modifications of SN‐38 and help reestablish the potential this drug. Furthermore, the inclusion of fluoro and bromo substituents means that the synthetic strategy developed here may be used to obtain 18 F‐ or 76 Br‐labeled SN‐38 derivatives for in vivo positron emission tomography studies.